To screen for, detect, and monitor treatment for congenital adrenal hyperplasia (CAH) due to a deficiency in the 21-hydroxylase enzyme; sometimes to help rule out other conditions.
17-Hydroxyprogesterone
1. in some countries as part of a routine newborn screen
2. when an infant has atypical genitalia i.e. it is unclear if the child is male or female
3. when a young female has hirsutism (excess hair) or other symptoms of virilisation
4. when a child has premature sexual development
5. periodically to monitor CAH treatment
6. in ‘salt-wasting’ presentations in infants
7. rarely in investigation of infertility
A blood sample is obtained by inserting a needle into a vein in the arm or by pricking the heel of an infant.
A saliva sample can be obtained by asking the patient to spit into a small container. Saliva samples may be suitable for analysis in some specialist laboratories.
There is no preparation such as fasting for this test, but the doctor may request an early morning collection. The doctor may also request that blood be collected in the first half of a woman's menstrual cycle.
-
How is it used?
TThe 17-hydroxyprogesterone (17-OHP) test can be part of a newborn screening programme in some countries. It is used to detect congenital adrenal hyperplasia (CAH), a group of inherited disorders caused by specific gene mutations associated with cortisol-related enzyme deficiencies (see ‘What is being tested’). About 90% of CAH cases are caused by a mutation in the CYP21A2 gene that leads to a 21-hydroxylase enzyme deficiency and to an increase of 17-OHP in the blood.
Newborns affected by severe 21- hydroxylase deficiency CAH may also produce less aldosterone, a hormone that regulates the retention of salt. The loss of too much fluid and salt in the urine can lead to a life-threatening "salt-wasting" crisis.
Positive 17-OHP screening tests may be repeated, or other tests performed, such as androstenedione and testosterone. An ACTH stimulation test may also be performed as a follow-up test. Molecular genetic testing may be performed to detect CYP21A2 gene mutations that cause the condition. A karyotype may be requested as a follow-up test to detect chromosome disorders and to help determine a baby's sex. Electrolytes are usually measured to help monitor the child’s blood sodium and potassium levels.
Measurement of 17-OHP in the blood may also be used to aid the diagnosis of CAH in older children and adults who may have a milder "non-classical" form.
If someone is diagnosed with 21-hydroxylase deficiency, treatment will involve replacement of the deficient cortisol with glucocorticoid treatment. A 17-OHP test may be used periodically to monitor the effectiveness of this treatment.
A 17-OHP test may also sometimes be used, with other hormone tests, to help rule out CAH in people who have symptoms,such as hirsutism and irregular periods. This includes women with suspected polycystic ovarian syndrome (PCOS) and infertility, and rarely those with suspected adrenal or ovarian cancers.
-
When is it requested?
The 17-OHP test can be part of a newborn screening programme in some countries.. A 17-OHP test may be requested whenever an infant has signs and symptoms of adrenal insufficiency or experiences salt-wasting crises. Some signs and symptoms may include:
- Listlessness, lack of energy (lethargy)
- Not eating well
- Dehydration
- Low blood pressure
An infant with congenital adrenal hyperplasia (CAH) may also have atypical genitalia, virilisation, acne, or pubic hair. This test may sometimes be requested in older children or in adults when the milder form of CAH is suspected. The 17-OHP test may also be conducted when a girl or woman is experiencing symptoms such as:
- Hirsutism
- Lack of or irregular periods (menses)
- Virilisation
- Infertility
In women, the symptoms are very similar to those of polycystic ovarian syndrome (PCOS). Boys or men may experience:
- Early (precocious) puberty
- Infertility
When a person has been diagnosed with 21-hydroxylase deficiency, then a 17-OHP test may be requested periodically to monitor the effectiveness of treatment.
-
What does the test result mean?
If a newborn or infant has significantly increased concentrations of 17-OHP, then it is likely that he or she has CAH due to 21-hydroxylase deficiency. If a person has moderately increased concentrations, then they may have a less severe form of CAH, a deficiency of another enzyme associated with CAH (such as 11beta-hydroxylase), or may have a false positive test.
Normal 17-OHP results mean that it is likely that the person does not have CAH due to a 21-hydroxylase deficiency. Low or decreasing concentrations in a person with CAH indicate a response to treatment. High or increasing concentrations may indicate that changes in treatment are required.
-
Is there anything else I should know?
Premature infants often have elevated concentrations of 17-OHP. The newborn screen may need to be repeated at a later time.
Rarely, prenatal 17-OHP testing may be performed on amniotic fluid to detect and treat CAH in the foetus during pregnancy.
-
Can I have CAH if no CYP21A2 gene mutations were detected during genetic testing?
Yes. Testing detects the most common mutations but will not detect those that are rare. If a specific mutation has been identified in your family line, then you should be tested for that mutation.
-
Can I have CAH with no symptoms of virilisation?
-
Is 21-hydroxylase deficiency CAH curable?
No, but it is treatable. Those with the condition will need to take glucocorticoids, and mineralocorticoids if their aldosterone is also low, throughout their life. In times of stress or illness, they may need extra medication to meet the needs of their body.